{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T00:22:44Z","timestamp":1793924564679,"version":"4.8.0"},"reference-count":95,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2024,3,5]]},"abstract":"<jats:sec id=\"ab-jrv240002-1\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Systemic amyloidosis from transthyretin (ATTR) protein is the most common type of amyloidosis that causes cardiomyopathy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv240002-2\">\n                    <jats:title>Observations<\/jats:title>\n                    <jats:p>\n                      Transthyretin (TTR) protein transports thyroxine (thyroid hormone) and retinol (vitamin A) and is synthesized predominantly by the liver. When the TTR protein misfolds, it can form amyloid fibrils that deposit in the heart causing heart failure, heart conduction block, or arrhythmia such as atrial fibrillation. The biological processes by which amyloid fibrils form are incompletely understood but are associated with aging and, in some patients, affected by inherited variants in the\n                      <jats:italic>TTR<\/jats:italic>\n                      genetic sequence. ATTR amyloidosis results from misfolded TTR protein deposition. ATTR can occur in association with normal\n                      <jats:italic>TTR<\/jats:italic>\n                      genetic sequence (wild-type ATTR) or with abnormal\n                      <jats:italic>TTR<\/jats:italic>\n                      genetic sequence (variant ATTR). Wild-type ATTR primarily manifests as cardiomyopathy while ATTR due to a genetic variant manifests as cardiomyopathy and\/or polyneuropathy. Approximately 50\u202f000 to 150\u202f000 people in the US have heart failure due to ATTR amyloidosis. Without treatment, heart failure due to ATTR amyloidosis is associated with a median survival of approximately 5 years. More than 130 different inherited genetic variants in\n                      <jats:italic>TTR<\/jats:italic>\n                      exist. The most common genetic variant is Val122Ile (pV142I), an allele with an origin in West African countries, that is present in 3.4% of African American individuals in the US or approximately 1.5 million persons. The diagnosis can be made using serum free light chain assay and immunofixation electrophoresis to exclude light chain amyloidosis combined with cardiac nuclear scintigraphy to detect radiotracer uptake in a pattern consistent with amyloidosis. Loop diuretics, such as furosemide, torsemide, and bumetanide, are the primary treatment for fluid overload and symptomatic relief of patients with ATTR heart failure. An ATTR-directed therapy that inhibited misfolding of the TTR protein (tafamidis, a protein stabilizer), compared with placebo, reduced mortality from 42.9% to 29.5%, reduced hospitalizations from 0.7\/year to 0.48\/year, and was most effective when administered early in disease course.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv240002-3\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>ATTR amyloidosis causes cardiomyopathy in up to approximately 150\u202f000 people in the US and tafamidis is the only currently approved therapy. Tafamidis slowed progression of ATTR amyloidosis and improved survival and prevented hospitalization, compared with placebo, in people with ATTR-associated cardiomyopathy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jama.2024.0442","type":"journal-article","created":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T11:13:39Z","timestamp":1709637219000},"page":"778","source":"Crossref","is-referenced-by-count":269,"title":["Cardiac Amyloidosis Due to Transthyretin Protein"],"prefix":"10.1001","volume":"331","author":[{"given":"Frederick L.","family":"Ruberg","sequence":"first","affiliation":[{"name":"Section of Cardiovascular Medicine, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston Medical Center, Boston, Massachusetts"},{"name":"Amyloidosis Center, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew S.","family":"Maurer","sequence":"additional","affiliation":[{"name":"Cardiac Amyloidosis Program, Seymour, Paul, and Gloria Milstein Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, and NewYork-Presbyterian Hospital, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"22","key":"jrv240002r1","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review.","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"jrv240002r2","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1080\/13506129.2022.2147636","article-title":"Amyloid nomenclature 2022: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee.","volume":"29","author":"Buxbaum","year":"2022","journal-title":"Amyloid"},{"issue":"12","key":"jrv240002r3","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.1111\/jgs.v70.12","article-title":"Analysis of lumbar spine stenosis specimens for identification of amyloid.","volume":"70","author":"Maurer","year":"2022","journal-title":"J Am Geriatr Soc"},{"issue":"17","key":"jrv240002r4","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1016\/j.jacc.2018.07.092","article-title":"Tenosynovial and cardiac amyloidosis in patients undergoing carpal tunnel release.","volume":"72","author":"Sperry","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"jrv240002r5","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075","article-title":"Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis.","volume":"12","author":"Maurer","year":"2019","journal-title":"Circ Heart Fail"},{"issue":"11","key":"jrv240002r6","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","article-title":"2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: a report of the American College of Cardiology Solution Set Oversight Committee.","volume":"81","author":"Kittleson","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"jrv240002r7","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1001\/jama.2020.5493","article-title":"Systemic amyloidosis recognition, prognosis, and therapy: a systematic review.","volume":"324","author":"Gertz","year":"2020","journal-title":"JAMA"},{"issue":"3","key":"jrv240002r8","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1080\/07853890701842988","article-title":"Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study.","volume":"40","author":"Tanskanen","year":"2008","journal-title":"Ann Med"},{"issue":"2","key":"jrv240002r9","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jchf.2013.11.004","article-title":"Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction.","volume":"2","author":"Mohammed","year":"2014","journal-title":"JACC Heart Fail"},{"issue":"3","key":"jrv240002r10","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1161\/CIRCULATIONAHA.115.018852","article-title":"Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: a prospective, observational cohort study.","volume":"133","author":"Connors","year":"2016","journal-title":"Circulation"},{"issue":"24","key":"jrv240002r11","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1093\/eurheartj\/ehx043","article-title":"Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths.","volume":"38","author":"Gonz\u00e1lez-L\u00f3pez","year":"2017","journal-title":"Eur Heart J"},{"issue":"38","key":"jrv240002r12","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.","volume":"36","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Eur Heart J"},{"issue":"38","key":"jrv240002r13","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","article-title":"Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement.","volume":"38","author":"Casta\u00f1o","year":"2017","journal-title":"Eur Heart J"},{"issue":"8","key":"jrv240002r14","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.116.005066","article-title":"Occult transthyretin cardiac amyloid in severe calcific aortic stenosis: prevalence and prognosis in patients undergoing surgical aortic valve replacement.","volume":"9","author":"Treibel","year":"2016","journal-title":"Circ Cardiovasc Imaging"},{"issue":"11","key":"jrv240002r15","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1001\/jamacardio.2021.3070","article-title":"Prevalence of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction.","volume":"6","author":"AbouEzzeddine","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"12","key":"jrv240002r16","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.122.014938","article-title":"Identification of transthyretin cardiac amyloidosis among patients previously diagnosed with hypertrophic cardiomyopathy.","volume":"15","author":"Rowin","year":"2022","journal-title":"Circ Cardiovasc Imaging"},{"issue":"12","key":"jrv240002r17","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1002\/ejhf.v24.12","article-title":"Redefining the epidemiology of cardiac amyloidosis: a systematic review and meta-analysis of screening studies.","volume":"24","author":"Aimo","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"jrv240002r18","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","article-title":"Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey).","volume":"68","author":"Maurer","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"jrv240002r19","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1056\/NEJMoa1404852","article-title":"V122I transthyretin variant in elderly Black Americans.","volume":"372","author":"Quarta","year":"2015","journal-title":"N Engl J Med"},{"issue":"15","key":"jrv240002r20","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.028973","article-title":"Clinical penetrance of the transthyretin V122I variant in older Black patients with heart failure: the SCAN-MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study.","volume":"12","author":"Madhani","year":"2023","journal-title":"J Am Heart Assoc"},{"issue":"7","key":"jrv240002r21","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1056\/NEJM199702133360703","article-title":"Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in Black Americans.","volume":"336","author":"Jacobson","year":"1997","journal-title":"N Engl J Med"},{"key":"jrv240002r22","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1750-1172-8-31","article-title":"Guideline of transthyretin-related hereditary amyloidosis for clinicians.","volume":"8","author":"Ando","year":"2013","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"jrv240002r23","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1002\/mus.v57.5","article-title":"Estimating the global prevalence of transthyretin familial amyloid polyneuropathy.","volume":"57","author":"Schmidt","year":"2018","journal-title":"Muscle Nerve"},{"issue":"5","key":"jrv240002r24","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGEN.121.003356","article-title":"Prevalence and outcomes of p.Val142Ile TTR amyloidosis cardiomyopathy: a systematic review.","volume":"14","author":"Chandrashekar","year":"2021","journal-title":"Circ Genom Precis Med"},{"issue":"22","key":"jrv240002r25","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2019.17935","article-title":"Association of the V122I hereditary transthyretin amyloidosis genetic variant with heart failure among individuals of African or Hispanic\/Latino ancestry.","volume":"322","author":"Damrauer","year":"2019","journal-title":"JAMA"},{"issue":"14","key":"jrv240002r26","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1001\/jama.2022.2896","article-title":"Association of transthyretin Val122Ile variant with incident heart failure among Black individuals.","volume":"327","author":"Parcha","year":"2022","journal-title":"JAMA"},{"issue":"7","key":"jrv240002r27","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/j.gim.2022.04.006","article-title":"ACMG SF v3.1 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG).","volume":"24","author":"Miller","year":"2022","journal-title":"Genet Med"},{"issue":"12","key":"jrv240002r28","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1002\/ejhf.v24.12","article-title":"Sex differences among patients with transthyretin amyloid cardiomyopathy: from diagnosis to prognosis.","volume":"24","author":"Patel","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"jrv240002r29","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/ejhf.v23.4","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases.","volume":"23","author":"Garcia-Pavia","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"jrv240002r30","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.cell.2005.01.018","article-title":"The biological and chemical basis for tissue-selective amyloid disease.","volume":"121","author":"Sekijima","year":"2005","journal-title":"Cell"},{"issue":"1","key":"jrv240002r31","doi-asserted-by":"publisher","first-page":"7112","DOI":"10.1038\/s41467-021-27416-z","article-title":"Plasmin activity promotes amyloid deposition in a transgenic model of human transthyretin amyloidosis.","volume":"12","author":"Slamova","year":"2021","journal-title":"Nat Commun"},{"issue":"4","key":"jrv240002r32","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1073\/pnas.1317488111","article-title":"Proteolytic cleavage of Ser52Pro variant transthyretin triggers its amyloid fibrillogenesis.","volume":"111","author":"Mangione","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"jrv240002r33","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system.","volume":"68","author":"Grogan","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"jrv240002r34","doi-asserted-by":"publisher","first-page":"142","DOI":"10.3109\/13506129.2013.797890","article-title":"Amyloid fibrils containing fragmented ATTR may be the standard fibril composition in ATTR amyloidosis.","volume":"20","author":"Ihse","year":"2013","journal-title":"Amyloid"},{"issue":"1","key":"jrv240002r35","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s12875-020-01252-4","article-title":"Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner.","volume":"21","author":"Gertz","year":"2020","journal-title":"BMC Fam Pract"},{"issue":"10","key":"jrv240002r36","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.jacc.2022.06.026","article-title":"Screening for cardiac amyloidosis 5 to 15 years after surgery for bilateral carpal tunnel syndrome.","volume":"80","author":"Westin","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"jrv240002r37","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.jchf.2019.04.010","article-title":"Screening for transthyretin amyloid cardiomyopathy in everyday practice.","volume":"7","author":"Witteles","year":"2019","journal-title":"JACC Heart Fail"},{"issue":"30","key":"jrv240002r38","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis.","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J"},{"issue":"19","key":"jrv240002r39","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1161\/CIRCULATIONAHA.107.186093","article-title":"The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology.","volume":"116","author":"Cooper","year":"2007","journal-title":"Circulation"},{"issue":"10","key":"jrv240002r40","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1161\/CIRCULATIONAHA.111.078915","article-title":"Transthyretin (TTR) cardiac amyloidosis.","volume":"126","author":"Ruberg","year":"2012","journal-title":"Circulation"},{"issue":"24","key":"jrv240002r41","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1093\/eurheartj\/ehx047","article-title":"Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis.","volume":"38","author":"Quarta","year":"2017","journal-title":"Eur Heart J"},{"issue":"9","key":"jrv240002r42","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1016\/j.mayocp.2020.06.029","article-title":"Amyloid typing by mass spectrometry in clinical practice: a comprehensive review of 16,175 samples.","volume":"95","author":"Dasari","year":"2020","journal-title":"Mayo Clin Proc"},{"issue":"22","key":"jrv240002r43","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1016\/j.jacc.2020.04.022","article-title":"Cardiac scintigraphy with technetium-99m-labeled bone-seeking tracers for suspected amyloidosis: JACC review topic of the week.","volume":"75","author":"Hanna","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"jrv240002r44","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-018-0034-3","article-title":"Systemic immunoglobulin light chain amyloidosis.","volume":"4","author":"Merlini","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"jrv240002r45","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1373\/clinchem.2008.117143","article-title":"Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine.","volume":"55","author":"Palladini","year":"2009","journal-title":"Clin Chem"},{"issue":"1","key":"jrv240002r46","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1080\/13506129.2018.1436048","article-title":"Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR).","volume":"25","author":"Phull","year":"2018","journal-title":"Amyloid"},{"issue":"11","key":"jrv240002r47","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1093\/ehjci\/jeab095","article-title":"99mTc-DPD scintigraphy in immunoglobulin light chain (AL) cardiac amyloidosis.","volume":"22","author":"Quarta","year":"2021","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"jrv240002r48","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.amjcard.2022.06.064","article-title":"Light chain testing abnormalities among patients with transthyretin amyloid cardiomyopathy referred for technetium-99m pyrophosphate imaging.","volume":"181","author":"Alreshq","year":"2022","journal-title":"Am J Cardiol"},{"issue":"24","key":"jrv240002r49","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis.","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"issue":"7","key":"jrv240002r50","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2-evidence base and standardized methods of imaging.","volume":"14","author":"Dorbala","year":"2021","journal-title":"Circ Cardiovasc Imaging"},{"issue":"7","key":"jrv240002r51","doi-asserted-by":"publisher","DOI":"10.1161\/HCI.0000000000000030","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 2 of 2-diagnostic criteria and appropriate utilization.","volume":"14","author":"Dorbala","year":"2021","journal-title":"Circ Cardiovasc Imaging"},{"issue":"6","key":"jrv240002r52","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1016\/j.jcmg.2019.10.015","article-title":"Low sensitivity of bone scintigraphy in detecting Phe64Leu mutation-related transthyretin cardiac amyloidosis.","volume":"13","author":"Musumeci","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"issue":"6","key":"jrv240002r53","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1016\/j.jcmg.2019.07.015","article-title":"How to image cardiac amyloidosis: a practical approach.","volume":"13","author":"Dorbala","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"issue":"10","key":"jrv240002r54","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1001\/jamacardio.2022.1781","article-title":"A Simple score to identify increased risk of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction.","volume":"7","author":"Davies","year":"2022","journal-title":"JAMA Cardiol"},{"issue":"18","key":"jrv240002r55","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1161\/CIRCULATIONAHA.113.006242","article-title":"Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis.","volume":"129","author":"Quarta","year":"2014","journal-title":"Circulation"},{"issue":"8","key":"jrv240002r56","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1093\/ehjci\/jead032","article-title":"Prevalence and significance of relative apical sparing in aortic stenosis: insights from an echo and cardiovascular magnetic resonance study of patients referred for surgical aortic valve replacement.","volume":"24","author":"Abecasis","year":"2023","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"6","key":"jrv240002r57","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.121.009025","article-title":"Cardiac amyloidosis: multimodal imaging of disease activity and response to treatment.","volume":"14","author":"Patel","year":"2021","journal-title":"Circ Cardiovasc Imaging"},{"issue":"3","key":"jrv240002r58","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.jaccao.2020.06.007","article-title":"Diuretic dose and NYHA functional class are independent predictors of mortality in patients with transthyretin cardiac amyloidosis.","volume":"2","author":"Cheng","year":"2020","journal-title":"JACC CardioOncol"},{"issue":"31","key":"jrv240002r59","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehad347","article-title":"Conventional heart failure therapy in cardiac ATTR amyloidosis.","volume":"44","author":"Ioannou","year":"2023","journal-title":"Eur Heart J"},{"issue":"1","key":"jrv240002r60","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association.","volume":"142","author":"Kittleson","year":"2020","journal-title":"Circulation"},{"issue":"18","key":"jrv240002r61","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/CIR.0000000000001063","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines.","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"issue":"24","key":"jrv240002r62","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.022859","article-title":"Lack of association between neurohormonal blockade and survival in transthyretin cardiac amyloidosis.","volume":"10","author":"Cheng","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"jrv240002r63","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/ehf2.v10.1","article-title":"SGLT2 inhibitor therapy for transthyretin amyloid cardiomyopathy: early tolerance and clinical response to dapagliflozin.","volume":"10","author":"Dobner","year":"2023","journal-title":"ESC Heart Fail"},{"issue":"5","key":"jrv240002r64","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/ehf2.v5.5","article-title":"Features of atrial fibrillation in wild-type transthyretin cardiac amyloidosis: a systematic review and clinical experience.","volume":"5","author":"Mints","year":"2018","journal-title":"ESC Heart Fail"},{"issue":"9","key":"jrv240002r65","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.jacep.2020.04.019","article-title":"Atrial fibrillation in transthyretin cardiac amyloidosis: predictors, prevalence, and efficacy of rhythm control strategies.","volume":"6","author":"Donnellan","year":"2020","journal-title":"JACC Clin Electrophysiol"},{"issue":"4","key":"jrv240002r66","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jacep.2020.01.004","article-title":"Management of arrhythmias in cardiac amyloidosis.","volume":"6","author":"Giancaterino","year":"2020","journal-title":"JACC Clin Electrophysiol"},{"issue":"18","key":"jrv240002r67","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1161\/CIRCULATIONAHA.108.785014","article-title":"Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis.","volume":"119","author":"Feng","year":"2009","journal-title":"Circulation"},{"issue":"13","key":"jrv240002r68","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1016\/j.jacc.2019.01.035","article-title":"High prevalence of intracardiac thrombi in cardiac amyloidosis.","volume":"73","author":"Martinez-Naharro","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"jrv240002r69","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.jacc.2020.10.057","article-title":"Persistence of left atrial appendage thrombus in patients with cardiac amyloidosis.","volume":"77","author":"El-Am","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"jrv240002r70","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/j.jacep.2019.10.013","article-title":"No association between CHADS-VASc score and left atrial appendage thrombus in patients with transthyretin amyloidosis.","volume":"5","author":"Donnellan","year":"2019","journal-title":"JACC Clin Electrophysiol"},{"issue":"1","key":"jrv240002r71","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1080\/13506129.2020.1810010","article-title":"Anticoagulation with warfarin compared to novel oral anticoagulants for atrial fibrillation in adults with transthyretin cardiac amyloidosis: comparison of thromboembolic events and major bleeding.","volume":"28","author":"Mitrani","year":"2021","journal-title":"Amyloid"},{"issue":"8","key":"jrv240002r72","doi-asserted-by":"publisher","first-page":"e382","DOI":"10.1161\/CIR.0000000000000628","article-title":"2018 ACC\/AHA\/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.","volume":"140","author":"Kusumoto","year":"2019","journal-title":"Circulation"},{"issue":"7","key":"jrv240002r73","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1002\/ejhf.v24.7","article-title":"Incidence and risk factors for pacemaker implantation in light-chain and transthyretin cardiac amyloidosis.","volume":"24","author":"Porcari","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"14","key":"jrv240002r74","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.017335","article-title":"Cardiac resynchronization therapy for transthyretin cardiac amyloidosis.","volume":"9","author":"Donnellan","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"11","key":"jrv240002r75","doi-asserted-by":"publisher","first-page":"e373","DOI":"10.1016\/j.hrthm.2019.09.019","article-title":"2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy: executive summary.","volume":"16","author":"Towbin","year":"2019","journal-title":"Heart Rhythm"},{"issue":"11","key":"jrv240002r76","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy.","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"jrv240002r77","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy.","volume":"390","author":"Gillmore","year":"2024","journal-title":"N Engl J Med"},{"issue":"24","key":"jrv240002r78","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1001\/jama.2013.283815","article-title":"Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial.","volume":"310","author":"Berk","year":"2013","journal-title":"JAMA"},{"issue":"1","key":"jrv240002r79","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis.","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"jrv240002r80","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis.","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"jrv240002r81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13506129.2022.2091985","article-title":"Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial.","volume":"30","author":"Adams","year":"2023","journal-title":"Amyloid"},{"issue":"15","key":"jrv240002r82","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1001\/jama.2023.18688","article-title":"Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy.","volume":"330","author":"Coelho","year":"2023","journal-title":"JAMA"},{"issue":"3","key":"jrv240002r83","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.jacc.2019.03.012","article-title":"Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid cardiomyopathy.","volume":"74","author":"Judge","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"jrv240002r84","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1080\/13506129.2021.2000388","article-title":"Diflunisal treatment is associated with improved survival for patients with early stage wild-type transthyretin (ATTR) amyloid cardiomyopathy: the Boston University Amyloidosis Center experience.","volume":"29","author":"Siddiqi","year":"2022","journal-title":"Amyloid"},{"issue":"1","key":"jrv240002r85","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s40120-021-00235-6","article-title":"Design and rationale of the global phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-LRx (ION-682884-CS3) in hereditary transthyretin-mediated amyloid polyneuropathy.","volume":"10","author":"Coelho","year":"2021","journal-title":"Neurol Ther"},{"issue":"1","key":"jrv240002r86","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s40120-022-00414-z","article-title":"Characteristics of patients with hereditary transthyretin amyloidosis-polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an open-label phase 3 study of eplontersen.","volume":"12","author":"Coelho","year":"2023","journal-title":"Neurol Ther"},{"issue":"4","key":"jrv240002r87","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis.","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation"},{"issue":"17","key":"jrv240002r88","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","article-title":"Patisiran treatment in patients with transthyretin cardiac amyloidosis.","volume":"389","author":"Maurer","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"jrv240002r89","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1056\/NEJMoa2303765","article-title":"Phase 1 trial of antibody NI006 for depletion of cardiac transthyretin amyloid.","volume":"389","author":"Garcia-Pavia","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"jrv240002r90","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.120.008193","article-title":"Long-term survival with tafamidis in patients with transthyretin amyloid cardiomyopathy.","volume":"15","author":"Elliott","year":"2022","journal-title":"Circ Heart Fail"},{"issue":"9","key":"jrv240002r91","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.cardfail.2019.11.024","article-title":"Stabilization of cardiac function with diflunisal in transthyretin (ATTR) cardiac amyloidosis.","volume":"26","author":"Lohrmann","year":"2020","journal-title":"J Card Fail"},{"issue":"4","key":"jrv240002r92","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.117.004769","article-title":"TTR (transthyretin) stabilizers are associated with improved survival in patients with TTR cardiac amyloidosis.","volume":"11","author":"Rosenblum","year":"2018","journal-title":"Circ Heart Fail"},{"issue":"4","key":"jrv240002r93","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.jaccao.2021.08.007","article-title":"Effect of tafamidis on serum transthyretin levels in non-trial patients with transthyretin amyloid cardiomyopathy.","volume":"3","author":"Falk","year":"2021","journal-title":"JACC CardioOncol"},{"issue":"4","key":"jrv240002r94","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1080\/13506129.2021.1904390","article-title":"Factors associated with changes in serum transthyretin after treatment with tafamidis and outcomes in transthyretin cardiac amyloidosis.","volume":"28","author":"Saith","year":"2021","journal-title":"Amyloid"},{"issue":"2","key":"jrv240002r95","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.ahj.2012.04.015","article-title":"Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS).","volume":"164","author":"Ruberg","year":"2012","journal-title":"Am Heart J"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2815711\/jama_ruberg_2024_rv_240002_1708623095.89021.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T11:13:43Z","timestamp":1709637223000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2815711"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2024,3,5]]},"references-count":95,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,3,5]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2024.0442","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,5]]}}}